Supplemental Figure 4 from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
Supplemental Figure S4. Progression-free survival Kaplan-Meier curves based on PET and ctDNA parameters. A. PFS based on baseline SUV categorized into lower and higher than median. B. PFS based on baseline tumor glycolysis level lower or higher than median. C. PFS based on baseline metabolic tumor volume (MTV) lower or higher than median.